{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:17:20Z","timestamp":1789823840711,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.leukres.2013.05.008","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T06:18:39Z","timestamp":1370326719000},"page":"1150-1155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-\u03b1 in CML cell line, KT-1 cells"],"prefix":"10.1016","volume":"37","author":[{"given":"Yuriko","family":"Nishiyama-Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatsune","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiko","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.05.008_bib0005","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0010","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.leukres.2013.05.008_bib0015","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.008_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.leukres.2013.05.008_bib0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2011.11.002","article-title":"Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression","volume":"39","author":"Ernst","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-9-99","article-title":"Advances in the treatment of chronic myeloid leukemia","volume":"9","author":"Eiring","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.leukres.2013.05.008_bib0035","first-page":"585","article-title":"BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of imatinib resistance in CML","volume":"39","author":"Hentschel","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Quentmeier","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0045","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2011-06-361261","article-title":"Targeting of GSK3b promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells","volume":"119","author":"Reddiconto","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0050","doi-asserted-by":"crossref","first-page":"10922","DOI":"10.1074\/jbc.M610157200","article-title":"Alterations of ceramide\/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells","volume":"282","author":"Baran","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2013.05.008_bib0055","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2011-03-341073","article-title":"SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia","volume":"118","author":"Esposito","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0060","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/blood-2010-08-300772","article-title":"Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A","volume":"117","author":"Salas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0065","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.leukres.2013.05.008_bib0070","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.leukres.2013.05.008_bib0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia","volume":"17","author":"O\u2019Hare","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.05.008_bib0080","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0301-472X(03)00089-4","article-title":"STI-571-resistant KT-1 cells are sensitive to interferon-\u03b1 accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1","volume":"31","author":"Shimizu","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0085","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.exphem.2004.07.024","article-title":"A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein","volume":"32","author":"Shimizu","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bbadis.2012.10.014","article-title":"The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl","volume":"1832","author":"Mitra","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2013.05.008_bib0095","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2013.05.008_bib0100","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0105","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"STAT: transcription control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0110","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1128\/MCB.22.16.5662-5668.2002","article-title":"Identification of a nuclear STAT1 protein tyrosine phosphatase","volume":"22","author":"ten Hoeve","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1210\/mend.16.1.0761","article-title":"A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus","volume":"16","author":"Aoki","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.V91.2.641","article-title":"Suppression of cell proliferation and expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-\u03b3","volume":"91","author":"Yanagisawa","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0125","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1128\/MCB.18.3.1622","article-title":"Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase","volume":"18","author":"Tiganis","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0130","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0960-9822(02)00697-8","article-title":"The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3","volume":"12","author":"Simoncic","year":"2002","journal-title":"Curr Biol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0140","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/MCB.01234-06","article-title":"T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphoma, is the nuclear phosphatase of STAT6","volume":"27","author":"Lu","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.leukres.2013.05.008_bib0145","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/ng.587","article-title":"Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia","volume":"42","author":"Kleppe","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2013.05.008_bib0150","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1182\/blood-2010-10-314286","article-title":"PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia","volume":"117","author":"Kleppe","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.008_bib0160","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon \u03b1-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.leukres.2013.05.008_bib0165","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.008_bib0170","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFN\u03b1 activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.05.008_bib0175","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","article-title":"Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type 1 interferon-dependent exhaustion","volume":"15","author":"Sato","year":"2009","journal-title":"Nat Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:29Z","timestamp":1758934709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613001574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0145212613001574"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.05.008","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-\u03b1 in CML cell line, KT-1 cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}